Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 10;11:3461. doi: 10.1038/s41598-021-83019-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Validation of anti-SARS-CoV-2 antibodies using electrochemiluminescence ELISA. (a) Schematic illustration of our new developed serological test. (b–g) Comparison of SARS-CoV-2 HRP-based ELISA to electrochemiluminescence-based ELISA. The presence of anti-RBD IgG and IgM antibodies was determined in a side-by-side comparison using HRP-based ELISA (HRP) (b,c) and electrochemiluminescence-based ELISA (TauMed) (d,e). The fold changes in the values obtained from individual positive samples (n = 4) over the average negative samples (n = 2) were calculated (f,g). (h–m) Validation of anti-SARS-CoV-2 antibodies using electrochemiluminescence ELISA. Peripheral blood was collected from the peripheral blood of > 14 DPS of hospitalized COVID-19 patients and anonymous recovered patients (n = 68 and n = 31 for RBD and NP respectively). Negative samples were obtained from true SARS-CoV-2 negative patients (i.e., prior to the SARS-CoV-2 pandemic) (n = 197 and n = 90 for RBD and NP respectively). Plasma was obtained, diluted 1:50, and added to a 96-well plate precoated with SARS-CoV-2 RBD (h–j) or NP (k–m) antigens. IgG (h,k), IgM (i,l), and IgA (j,m) levels as well as ROC analysis are shown. Data were calculated using GraphPad Prism 8; the dotted line represents the calculated cutoff value discriminating between positive and negative samples. A nonparametric Mann–Whitney t-test was performed. P values are shown.